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Abstract
Aims Hypertension is the leading cause for the development of heart failure (HF). Here, we aimed to identify cardiomyocyte
stretch-induced circulating biomarkers for predicting hypertension-associated HF.
Methods and results Circulating levels of 149 proteins were measured by proximity extension assay at baseline examination
in 4742 individuals from the Malmö Diet and Cancer study. Protein levels were compared with stretch-activated gene expres-
sion changes in cultured neonatal rat ventricular myocytes (NRVMs) in response to 1–48 h of mechanical stretch. We also stud-
ied the association between protein levels and hypertension and HF incidence using respectively binary logistic and Cox
regressions. Levels of 35 proteins were differentially expressed after Bonferroni correction in incident HF vs. control
(P < 3.4E4). Growth differentiation factor-15 (GDF-15), interleukin-6 (IL-6), IL-1 receptor type 1, and urokinase plasminogen
activator surface receptor had corresponding mRNA levels up-regulated by stretch in NRVMs at all time points (P < 0.05).
These four proteins were individually associated with increased risk of HF after age and sex adjustment [hazard ratio (HR)
per standard deviation: 1.19 ≤ HR ≤ 1.49, P ≤ 4.90E3]. GDF-15 and IL-6 were associated with HF independently of each other
(1.22 ≤ HR ≤ 1.33, P ≤ 0.001). In subjects with hypertension, these associations remained significant after further adjustment
for N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (1.23 ≤ HR ≤ 1.45, P ≤ 0.001). A higher fasting value of a GDF-
15, IL-6 score aggregate was associated with increased risk of hypertensive HF after adjustment for all traditional risk factors
for HF and NT-proBNP (HR = 1.31, P = 2.19E4).
Conclusions Cardiomyocyte mRNA levels of GDF-15 and IL-6 are consistently up-regulated by stretch, and their circulating
protein levels predict HF in hypertensive subjects independently of NT-proBNP during long-term follow-up. Our results encour-
age further studies on lower blood pressure goals in hypertensive subjects with high GDF-15 and IL-6, and interventions
targeted at stretch-induced cardiomyocyte expressed biomarkers.
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Introduction
Heart failure (HF) is characterized by inadequate cardiac func-
tion for maintaining and supporting an individual’s physiolog-
ical requirement and results in frequent hospitalizations,
impaired quality of life, and high mortality.1 Lifetime risk to
develop HF ranges from 20% to 45% depending on sex and
race.2 HF is a heterogeneous syndrome with different
pathomechanisms, including neurohormonal activation, in-
flammation, myocardial stretch, matrix remodelling, and car-
diomyocyte injury.3 However, hypertension is the single most
important modifiable risk factor for HF.4
Although pro-B-type natriuretic peptide (BNP) level is a
recognized biomarker for HF risk prediction,5,6 additional
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plasma biomarkers for HF incidence are emerging (for review,
see Ibrahim and Januzzi7), but it is uncertain if they specifi-
cally reflect cardiomyocyte dysfunction or injury. The pheno-
typic feature of mechanically stretched cardiomyocytes
in vitro mimics that of pressure overload-induced cardiac
hypertrophy in vivo.8 It thus provides a well-defined experi-
mental model to study HF related to hypertension (i.e. hyper-
tensive HF).
Here, we examined if plasma protein biomarkers that can
be proven to be induced in cardiomyocytes by cardiovascular
stress predict HF outcome in a general population. To do so,
we combined gene expression profiling data from an in vitro
cardiomyocyte stretch model with measurements in a pro-
spective population-based cohort of a panel of circulating
proteins known or suggested to be involved in cardiovascular
disease, cell proliferation, differentiation, or death. Given the
focus on stretch-activated cardiomyocyte biomarkers, we
also stratified our analyses for presence vs. absence of hyper-
tension at baseline examination.
Materials and methods
Study participants and data collection
The Malmö Diet and Cancer–Cardiovascular Cohort (MDC-CC)
is a prospective population-based cohort designed to study
the epidemiology of carotid artery disease collected from
1991 through 1994.9 At baseline, all the MDC-CC participants
underwent medical history, physical examination, and labora-
tory and lifestyle assessment. Of the 5405 participants who
came fasted, plasma samples were available in 4742 subjects
for analysis of a panel of proteins.
Systolic blood pressure (SBP) and diastolic blood pressure
were measured using a mercury-column sphygmomanometer
after 10 min of rest in the supine position. Data on current
smoking and use of antihypertensive treatment were
ascertained from a baseline questionnaire.10 Body mass index
(BMI) was calculated as weight in kilograms divided by the
square of the height in metres. Diabetes mellitus (DM) at
baseline was defined as a fasting whole blood
glucose > 6.0 mmol/L or self-report of a physician diagnosis
or use of diabetes medication. Hypertension at baseline was
defined as SBP ≥ 140 mmHg or diastolic blood
pressure ≥ 90 mmHg or being on antihypertensive treatment.
All participants provided written informed consent, and
the study was approved by the Ethics Committee at Lund
University.
Follow-up and endpoint retrieval
Heart failure was defined as the first incident hospitalization
with HF as main diagnosis, and incident cases of HF were
included irrespective of co-morbid diagnoses. The endpoints
were retrieved through record linkage of the personal
identification number of each Swedish citizen with Swedish
local or national registries as described previously11 until 31
December 2016.
Laboratory measurements
All laboratory assays were performed on overnight-fasted
blood samples obtained at the time of the baseline examina-
tion. Analysis of plasma high-density lipoprotein cholesterol
(HDL-C) was performed according to standard procedures at
the Department of Clinical Chemistry, Skåne University Hospi-
tal in Malmö. The levels of low-density lipoprotein cholesterol
(LDL-C) were calculated according to the Friedewald formula.
N-terminal pro-BNP (NT-proBNP) levels were determined
using the Dimension RxL automated NT-proBNP method
(Siemens Diagnostics, Nürnberg, Germany).12
Plasma levels of 149 proteins were measured using Olink
Proseek Multiplex proximity extension assay (PEA) at the
Clinical Biomarkers Facility, Science for Life Laboratory,
Uppsala, Sweden. PEA uses two highly specific oligonucleo-
tide labelled antibodies per protein, which allows the forma-
tion of a PCR reporter sequence when both antibodies are
bound to the target protein’s surface. This sequence is then
quantified by real-time quantitative PCR.13 Data are
expressed as normalized protein expression arbitrary units.
Gene expression profiling of stretch-regulated
genes in cardiomyocytes
We have reported previously the cardiomyocyte gene expres-
sion profiling results that showed statistically differential ex-
pression of 205, 579, 737, 621, and 1542 genes in response
to 1, 4, 12, 24, and 48 h of mechanical stretching,
respectively14 (GEO accession number GSE107551).
Briefly, primary cultures of neonatal rat ventricular
myocytes were prepared from 2- to 4-day-old Sprague–
Dawley rats, plated at a density of 2 × 105/cm2 on flexible
bottomed collagen I-coated 6-well elastomere plates (BioFlex,
Flexcell International Corporation, Hillsborough, NC, USA) and
cultured overnight as described previously.15 Cyclic mechani-
cal stretch for 15 min to 48 h was performed in vitro using a
Flexercell Strain Unit FX-3000 apparatus (Flexercell Int. Corp.,
McKeesport, PA, USA). The amplitude of stretch varied be-
tween 10% and 25% at 0.5 Hz frequency. The vacuum varied
in 2 s cycles at a level sufficient to promote cyclic stretch of
the cardiomyocytes at the point of maximal distension of
the culture surface. The effect of “ageing” was avoided by
starting the stretch stepwise in the experimental groups
and finished simultaneously to avoid of the cells in culture.
The experiments were carried out in two separate sets, each
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having their own control: (i) 1, 4, and 12 h and (ii) 24 and 48 h
of stretch. Afterwards, the cells were quickly frozen with ni-
trogen oxide and stored at 70°C. Total RNA was isolated,
and gene expression profiling was performed using the
GeneChip Rat Expression Set 230_2.0 Array (Affymetrix,
Santa Clara, CA, USA).14 The Affymetrix CEL files were
imported into GENESPRINGTM GX 12.6 software (Agilent
Technologies), and Robust Multichip Average normalization
was performed. Genes were defined as differentially
expressed if the fold change was at least 1.5-fold and statisti-
cally significant (P < 0.05, one-way ANOVA and Benjamini
and Hochberg false discovery rate) (Rysä, Tokola, Ruskoaho).
Statistical analyses
SPSS (version 25.0) was used for all statistical analyses.
Because of non-normality, fasting plasma concentration of
all 149 proteins and NT-proBNP were transformed with the
natural logarithm. For all statistical analyses, except for
Student’s t-test, the studied proteins were scaled to multiples
of one standard deviation (SD) and centred on zero prior
analysis. Participants with prevalent HF were excluded as well
as those with missing measurement of NT-proBNP, leaving
4469 individuals for statistical analyses.
Student’s t-tests and Pearson χ2 tests were used to com-
pare respectively the continuous and dichotomous variables
at baseline examination. Student’s t-tests were also used to
compare plasma levels of the 149 proteins between incident
HF and participants who remained free from HF during
follow-up. Logistic regression models adjusted for age and
sex were used to analyse the associations between baseline
levels of growth differentiation factor-15 (GDF-15),
interleukin-6 (IL-6), IL-1 receptor like 1 (referred to as soluble
ST2 and abbreviated as ST2), urokinase plasminogen activator
surface receptor (uPAR), and hypertension at baseline exam-
ination. The associations between GDF-15, IL-6, ST2, uPAR,
and HF incidence were investigated using multivariable Cox
proportional hazards models. Hazard ratios (HRs) were
expressed per SD increment of protein level. Model 1 was ad-
justed for age and sex. Model 2 was adjusted for age, sex,
and all four proteins. Model 3 was adjusted for age, sex,
NT-proBNP levels, BMI, SBP, current smoking, prevalent
DM, and fasting plasma levels of LDL-C and HDL-C. Partial
Spearman correlation was used to test for association be-
tween SBP and plasma levels of GDF-15 and IL-6 adjusting
for age and sex. The associations between GDF-15, IL-6, and
HF incidence stratifying for hypertension were investigated
using multivariable Cox proportional hazards models. Model
1 was adjusted for age and sex. Model 2 was adjusted for
age, sex, and NT-proBNP levels; and Model 3 was further ad-
justed for GDF-15 and IL-6. Finally, Model 4 was adjusted for
age, sex, NT-proBNP levels, BMI, SBP, current smoking, prev-
alent DM, and fasting plasma levels of LDL-C and HDL-C.
A GDF-15, IL-6 score was created in the participants with
hypertension at baseline by summing the standardized values
of the respective protein levels. Kaplan–Meier survival curve
was used to describe the rate of primary HF in quartiles of
baseline levels of the GDF-15, IL-6 score. Multivariable Cox
proportional hazards models were adopted to examine the
association between the GDF-15, IL-6 score and incident HF.
Model 1 was adjusted for age, sex, and NT-proBNP levels.
Model 2 was further adjusted for BMI, SBP, current smoking,
prevalent DM, and fasting plasma levels of LDL-C and HDL-C.
Participants without complete data on covariates were ex-
cluded from the analysis. HRs were expressed per SD incre-
ment of the GDF-15, IL-6 score, or per increasing quartiles
of the score (quartiles 2 through 4 compared with quartile 1).
Receiver operating characteristic (ROC) curves were con-
structed to assess the predictive ability of different models.
Bonferroni correction was used to determine significance
for the multiple tests performed to compare plasma levels
of the 149 proteins in incident HF vs. HF-free participants.




The characteristics of the study participants at baseline exam-
ination are listed in Table 1. Among 4469 participants free
from HF at baseline examination, 284 developed new-onset
HF during a median follow-up time of 23.4 years (25–75%
inter-quartile range 20.3–24.3). Almost all traditional risk
factors for HF were significantly more disadvantageous in in-
dividuals with incident HF compared with controls.
Plasma levels of a protein panel and heart failure
Overnight-fasted plasma levels of 149 proteins at baseline
examination were compared between incident HF and
participants who remained free from HF during follow-up
(Table S1). A total of 35 protein biomarkers were significantly
different after Bonferroni correction for multiple testing
(P < 3.4E4), of which all were elevated in incidence HF vs.
controls (Table S1).
Gene expression levels in stretched
cardiomyocytes
Our recent gene expression profiling study of neonatal rat
ventricular myocytes characterized the transcriptional pro-
files triggered by 1–48 h of mechanical stretch.14 Out of the
proteins with elevated baseline levels in HF incidence, 13
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were also dysregulated at gene expression level in stretched
cardiomyocytes (Table S2), of which four (GDF-15, IL-6, ST2,
and uPAR) were statistically significantly up-regulated at all
the time points examined (1, 4, 12, 24, and 48 h) (P < 0.05)
(Figure 1A,B).
Protein levels and hypertension
Among the 4469 study participants, 2810 were hypertensive
at baseline examination. In a next step, we investigated if
baseline plasma levels of GDF-15, IL-6, ST2, and uPAR were
associated with hypertension. In models adjusted for age
and sex, there was a statistically significant positive correla-
tion between the three biomarkers GDF-15, IL-6 and ST2
and hypertension (P ≤ 2.2E3) (Table S3).
Protein levels and risk of heart failure
Next, we tested if plasma levels of GDF-15, IL-6, ST2, and
uPAR are associated with HF incidence (Table 2). A higher
Table 1 Population characteristics
Controls (n = 4185) Incident HF (n = 284) Pa
Age (years) 57.17 ± 5.94 61.07 ± 4.84 7.34E27
Sex, n (% women) 2572 (61.5) 134 (47.2) 1.91E06
BMI (kg/m2) 25.56 ± 3.82 27.67 ± 4.77 1.20E18
Fasting LDL-C (mmol/L) 4.16 ± 0.98 4.20 ± 0.99 0.49
Fasting HDL-C (mmol/L) 1.40 ± 0.37 1.30 ± 0.35 1.26E05
SBP (mmHg) 140.28 ± 18.60 149.01 ± 20.01 3.25E14
DBP (mmHg) 86.46 ± 9.22 89.82 ± 9.56 3.42E09
NT-proBNP (pg/mL) 93.18 ± 139.63 201.98 ± 576.71 5.28E19
Diabetes prevalence, n (%) 286 (6.8) 51 (18.0) 6.41E12
Antihypertensive medication use, n (%) 627 (15.0) 113 (39.8) 1.38E27
Smoker, n (%) 1086 (26.0) 81 (28.6) 0.328
Values are displayed as M ± SD or frequency in per cent.
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density li-
poprotein cholesterol; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood pressure.
aP values were obtained from Student’s t-tests for the continuous variables or from Pearson χ2 tests for the binary variables.
Figure 1 Circulating proteins up-regulated in incidence of heart failure with corresponding stretch-activated gene expression changes in cultured neo-
natal rat ventricular myocytes in response to 1, 4, 12, 24, or 48 h of cyclic mechanical stretch. Venn diagrams indicate the overlap of the genes (bold)
that were significantly up-regulated (>1.5-fold) compared with non-stretched cells in all time points. AM, adrenomedullin; BNP, B-type natriuretic pep-
tide; CCL20, C-C motif chemokine ligand 20; CHI3L1, chitinase 3-like 1; CXCL10, C-X-C motif chemokine ligand 10; CXCL13, C-X-C motif chemokine ligand
13; FABP4, fatty acid binding protein 4; FS, follistatin; GDF-15, growth differentiation factor-15; IL-6, interleukin 6; TNFRSF11B, TNF receptor superfamily
member 11b; ST2, interleukin 1 receptor type I; uPAR, urokinase plasminogen activator receptor.
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fasting value of each of these four biomarkers was associated
with increased risk of HF after age and sex adjustment
(1.19 ≤ HR ≤ 1.49, P ≤ 4.90E3) (Model 1, Table 2). The
associations remained significant in a fully adjusted model
for all traditional HF risk factors (1.17 ≤ HR ≤ 1.27, P ≤ 0.02)
(Table S4). The area under the ROC curve was 0.773 (95%
CI, 0.746–0.800) for all the traditional risk factors and
changed to 0.774 (95% CI, 0.747–0.801) when GDF-15, IL-6,
ST2, and uPAR were added to the model.
We also studied if the four proteins were associated with
future HF independently of each other by incorporating all
four biomarkers in the same Cox proportional hazards model.
Higher fasting levels of both GDF-15 and IL-6 were indepen-
dently associated with increased risk of HF after adjustment
for age and sex (HR = 1.33, CI = 1.12–1.58, P = 0.001 and
HR = 1.22, CI = 1.10–1.37, P = 3.72E4, respectively) (Model
2, Table 2). However, ST2 and uPAR were no longer signifi-
cantly associated with HF incidence and were thus not further
investigated.
Growth differentiation factor-15 and
interleukin-6 levels in hypertensive heart failure
There was a positive correlation between SBP and plasma
levels of GDF-15 and IL-6 (r = 0.07, P < 0.001 and r = 0.11,
P < 0.001, respectively). In a next step, we tested if plasma
levels of GDF-15 and IL-6 were associated with the risk of
HF in normotensive (1659 individuals, of which 46 developed
new-onset HF) and in hypertensive individuals (2810 individ-
uals, of which 238 developed new-onset HF). None of the
proteins were associated with the incidence of HF in normo-
tensive individuals. However, higher plasma levels of GDF-15
and IL-6 were individually associated with increased risk of HF
in hypertensive individuals after adjusting for age and sex
(P ≤ 4.7E9) (Model 1, Table 3). The relationships remained
statistically significant after further adjustment for fasting
plasma NT-proBNP levels, (P ≤ 6.3E8) (Model 2, Table 3)
as well as further adjustment for BMI, SBP, current smoking,
prevalent DM, and fasting plasma levels of LDL-C and HDL-C
(HR = 1.27, CI = 1.10–1.47, P = 0.001 and HR = 1.21,
CI = 1.06–1.38, P = 0.004, respectively). Furthermore,
GDF-15 and IL-6 were associated with HF in hypertensive par-
ticipants independently of each other in a model adjusted for
age, sex, and NT-proBNP levels (HR = 1.32, CI = 1.14–1.53,
P = 2.3E4 and HR = 1.23, CI = 1.09–1.39, P = 0.001, respec-
tively) (Model 3, Table 3).
Protein score and hypertensive heart failure
We aggregated levels of GDF-15 and IL-6 into a score by sum-
ming the standardized values of the respective protein levels
in the 2810 participants with hypertension at baseline exam-
ination. The cumulative incidence rate of HF according to
quartiles of baseline fasting plasma concentration of the
GDF-15, IL-6 score was higher for subjects in the upper quar-
tiles (Figure 2). A higher value of the biomarker score was as-
sociated with increased risk of HF in individuals with
hypertension after adjusting for age, sex, and fasting plasma
levels of NT-proBNP (Model 1) (HR = 1.51, CI = 1.33–1.71,
P = 1.03E10) (Table 4). The association remained significant
after further adjustment for BMI, SBP, current smoking, prev-
alent DM, and fasting plasma levels of LDL-C and HDL-C at
baseline (Model 2), with a multivariable adjusted HR of 1.31
(95% CI, 1.14–1.51, P = 2.19E4) per one SD increment of
the GDF-15, IL-6 score for risk of future HF (Tables 4 and
S5). There was a linear relationship between the GDF-15,
IL-6 score and the risk of incident HF in both Models 1 and
2 (P for trend respectively equal to 5.23E9 and 0.001),
and the top vs. bottom quartile of the protein score in the
fully adjusted model was associated with an HR of 2.26
(95% CI, 1.36–3.77) (Table 4). In the hypertensive subpopula-
tion, the area under the ROC curve was 0.751 (95% CI,
0.720–0.782) for all the traditional risk factors and changed
to 0.754 (95% CI, 0.723–0.784) when the GDF-15, IL-6 score
was added to the model.
Table 2 Circulating protein levels and incidence of heart failure
HF (n = 284/4185)
Biomarkers
GDF-15 IL-6 ST2 uPAR
Model 1
HR per SD (95% CI) 1.49 (1.31–1.68) 1.34 (1.22–1.48) 1.19 (1.06–1.35) 1.34 (1.18–1.51)
P 3.80E10 9.47E10 4.90E03 2.86E06
Model 2
HR per SD (95% CI) 1.33 (1.12–1.58) 1.22 (1.10–1.37) 1.02 (0.89–1.17) 1.03 (0.88–1.22)
P 0.001 3.72E04 0.737 0.692
Values are hazard ratios (95% confidence intervals) for incidence of heart failure per SD unit increase of protein from Cox proportional
hazards models. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, and all four biomarkers together.
CI, confidence interval; GDF-15, growth differentiation factor-15; HF, heart failure; IL-16, interleukin-16; uPAR, urokinase plasminogen ac-
tivator receptor.
GDF-15 and IL-6 in hypertensive heart failure risk prediction 1895
ESC Heart Failure 2020; 7: 1891–1899
DOI: 10.1002/ehf2.12757
Discussion
We here demonstrate that GDF-15 and Il-6, which are in-
duced in cardiomyocytes in response to mechanical over-
load, were associated with increased incidence of HF
during long-term follow-up in a community-based popula-
tion. We also established that in participants developing hy-
pertensive HF, GDF-15 and IL-6 provided prognostic
information independently of the established biomarker
NT-proBNP both as single biomarkers and as a combined
score.
Table 3 Circulating protein levels and incidence of heart failure





HR per SD (95% CI) P HR per SD (95% CI) P
Model 1
GDF-15 1.32 (0.95–1.83) 0.100 1.49 (1.31–1.71) 4.71E09
IL-6 1.15 (0.89–1.47) 0.278 1.39 (1.25–1.55) 1.44E09
Model 2
GDF-15 1.31 (0.95–1.81) 0.095 1.45 (1.27–1.66) 4.36E08
IL-6 1.14 (0.88–1.48) 0.309 1.35 (1.21–1.50) 6.30E08
Model 3
GDF-15 1.28 (0.91–1.80) 0.162 1.32 (1.14–1.53) 2.31E04
IL-6 1.07 (0.79–1.43) 0.675 1.23 (1.09–1.39) 0.001
Values are hazard ratios (95% confidence intervals) for incidence of
heart failure per SD unit increase of protein from Cox proportional
hazards models. Model 1 is adjusted for age and sex. Model 2 is ad-
justed for age, sex, and fasting plasma levels of N-terminal pro-B-
type natriuretic peptide. Model 3 is further adjusted for GDF-15
and IL-6.
CI, confidence interval; GDF-15, growth differentiation factor-15;
HF, heart failure; IL-16, interleukin-1.
Figure 2 Cumulative incidence rate of heart failure events according to quartiles of a multiple-marker score with GDF-15 and IL-6 aggregated levels in
hypertensive individuals (n = 2810). GDF-15, growth differentiation factor-15; IL-6, interleukin 6.
Table 4 Incidence of heart failure in hypertensive individuals in re-









HRc per SD 1.51 (1.33–1.71) 1.31 (1.14–1.51)
P 1.03E10 2.19E04
Quartiles
HRd Q1 1.0 (reference) 1.0 (reference)
HRd Q2 1.85 (1.10–3.10) 1.62 (0.96–2.73)
HRd Q3 2.76 (1.68–4.51) 2.10 (1.27–3.47)
HRd Q4 3.61 (2.22–5.87) 2.26 (1.36–3.77)
P for trende 5.23E09 0.001
HF, heart failure; HR, hazard ratio.
aModel 1 was adjusted for: age, sex and plasma concentration of
N-terminal pro-B-type natriuretic peptide at baseline.
bModel 2 was adjusted for: age, sex, body mass index, systolic
blood pressure, current smoking, prevalent diabetes mellitus,
and fasting plasma levels of low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and N-terminal pro-B-type
natriuretic peptide at baseline. In Model 2, individuals without in-
complete data on covariates were excluded from the analysis.
cHRs are expressed per 1-SD increment of the growth differentia-
tion factor-15 (GDF-15), interleukin-16 (IL-6) score. 95% confi-
dence intervals of the HRs are reported in parentheses.
dHRs are expressed as categories of the GDF-15, IL-6 score quartiles
using quartile 1 as reference. 95% confidence intervals of the HRs
are reported in parentheses.
eP for trend across quartiles of the GDF-15, IL-6 score in a linear re-
gression model.
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We identified several proteins with elevated plasma levels
in apparently healthy participants who developed HF later in
life as compared with individuals remaining HF free. Four of
these biomarkers displayed a cardiomyocyte-specific constant
up-regulation in response to mechanical stretch, GDF-15, IL-6,
uPAR (inflammation markers), and ST2 (myocyte stress and fi-
brosis marker). Regulation of GDF-15 by stretch was in concor-
dance with a previous study.16 The fact that the four
biomarkers of up-regulation already started after 1 h of stretch
in cardiomyocytes and wasmaintained under 48 h indicates an
early and consistent cellular response to pressure overload. In-
terestingly, an increase in plasma levels of GDF-15, IL-6, and
ST2 was measured in human plasma of hypertensive subjects.
Furthermore, circulating GDF-15, IL-6, uPAR, and ST2 were in-
dividually associated with new-onset HF. It has previously
been reported that elevated plasma levels of uPAR were asso-
ciated with an increased risk of HF in the MDC-CC,17 and we
here confirmed this finding using another type of laboratory
measurement (PEA vs. ELISA). Previous studies have also
shown that levels of circulating ST2 were a predictor of inci-
dent HF in prospective cohorts of middle-aged18 and elderly
participants.19 When we combined the four biomarkers in
the same regression model in an attempt to identify different
pathophysiological pathways for HF, only GDF-15 and IL-6
remained significantly associated with HF incidence. We thus
focused this study on these two biomarkers.
Growth differentiation factor is a stress-responsive mem-
ber of the transforming growth factor-β cytokine superfamily
and is expressed and secreted in response to inflammation.20
In middle-aged Framingham Heart Study participants, plasma
levels of GDF-15 predicted incident HF in both single-marker
and multiple-marker analyses that accounted for traditional
risk factors and BNP in the multimarker model.18,21 We here
repeat the finding of GDF-15 being predictive of HF indepen-
dently of NT-proBNP in another prospective cohort of
middle-aged participants. Furthermore, we extend the results
by showing an association between GDF-15 and incident HF
independently of NT-proBNP in participants with overt hyper-
tension, and by having a much longer follow-up time to event
(median 23.4 vs. 14.3 years).
Interleukin-6 is a soluble cytokine with pleiotropic effects
in inflammation and has been shown to be involved in the de-
velopment of HF. Despite no association between circulating
IL-6 levels and incident HF in offspring from the Framingham
Heart Study,21 IL-6 was found to be associated with an in-
creased risk for congestive HF independently of traditional
risk factors in two different cohorts of elderly with short
follow-up time (mean 3.6–5.2 years).22,23 We here broaden
these observations to encompass middle-aged subjects with
long time to event. Furthermore, we established an associa-
tion between IL-6 and incident hypertensive HF, which was
independent of NT-proBNP.
Growth differentiation factor-15 and IL-6 remained inde-
pendently associated with hypertensive HF when combined
in the same model, which indicates that they reflect different
pathways of HF pathophysiology. Furthermore, the GDF-15
and IL-6 aggregated score predicted hypertensive HF inde-
pendently of the traditional risk factors for HF and NT-
proBNP, which suggests that measurement of GDF-15 and
IL-6 might add complementary information with respect to
prediction of HF in subjects with hypertension.
Regarding potential therapeutic implications, patients with
symptomatic HF treated for 12 months with valsartan, an an-
giotensin II receptor antagonist, had reduced BNP but not
GDF-15 levels as compared with the placebo group.24 This in-
dicates that GDF-15 and BNP have different underlying regu-
latory mechanisms in HF. However, based on the
pathobiology of GDF-15 and the role of systemic inflamma-
tion in hypertension, anti-inflammatory, anti-oxidant, or
anti-aging therapies may be more beneficial to individuals
with hypertension and increased GDF-15 levels.20 In patients
with previous myocardial infarction, treatment with
canakinumab, an IL-1β inhibitor, reduced circulating levels
of IL-6 in a dose-dependent manner,25 and there was a statis-
tically significant trend over the three tested doses for a re-
duction in the risk of HF.26 This further raises the possibility
that anti-inflammatory therapy could also be protective
against HF development in hypertensive patients, especially
in patients with high levels of GDF-15 and IL-6.
This study has several limitations that deserve to be men-
tioned. Although we investigated a large number of proteins
on the basis of existing evidence for associations with cardio-
vascular disease, cell proliferation, differentiation, or death,
we might be missing some relevant proteins with our
targeted approach. Furthermore, protein levels were
assessed by the multiplex antibody-based PEA, and confirma-
tion with other immunoassays would be beneficial. In the
stretch model, measurements were only performed at the
transcriptional level, although it would have been informative
to also determine protein levels. In addition, almost
two-thirds of the study participants were hypertensive at
baseline examination, and we might thus be underpowered
to study normotensive HF incidence. Finally, although we
demonstrated experimentally that GDF-15 and IL-6 are mod-
ulated by mechanical stretch in cardiomyocytes, we cannot
exclude that in response to hypertension, other cell types
and organs contribute to an elevation of plasma GDF-15
and IL-6 levels especially because those biomarkers are not
cardiomyocyte specific. For example, under pathological con-
ditions, GDF-15 can be produced by both cardiovascular and
noncardiovascular cell types,20 and circulating levels of IL-6
may be modulated by physical exercise and stress.27
In conclusion, by using a proteomic platform, we identified
35 circulating protein biomarkers that were associated with
incident HF, and four of these were persistently dysregulated
by mechanical stretch in cardiomyocytes. As a combined
score, GDF-15 and IL-6 were associated with long-term inci-
dent HF in subjects with hypertension after accounting for
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potential clinical cofounders and NT-proBNP. Thus, plasma
levels of GDF-15 and IL-6 could be used as biomarkers specific
for early cardiomyocytes dysfunction or injury due to hyper-
tension and thus to monitor the pathophysiological process
ultimately susceptible to lead to HF.
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Table S1. Plasma protein levels at baseline examination in
participants that developed heart failure (HF) under
follow-up and in those that remained free from HF during
follow-up time. Bold denotes proteins induced by stretch in
cardiomyocytes at all time points. See olink proteomics
website for the protein biomarkers full name (https://www.
olink.com/products/complete-protein-biomarkers-list/).
Table S2. Circulating proteins upregulated in incidence of
heart failure with corresponding gene expression changes in
cultured neonatal rat ventricular myocytes (NRVM)s in re-
sponse to 1, 4, 12, 24 or 48 hours of cyclic mechanical stretch.
Bold denotes proteins induced by stretch in cardiomyocytes
at all time points.
Table S3. Circulating protein levels in hypertension
Table S4. Circulating protein levels and incidence of heart fail-
ure
Table S5. Incidence of heart failure in hypertensive individ-
uals in relation to baseline levels of a score for GDF-15 and
IL-6 aggregated levels in a fully adjusted model.
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